San Francisco, CA – October 16, 2025 – Graph AI, a California-based AI life sciences startup specializing in patient safety and pharmacovigilance, has raised $3 million in a seed funding round led by Bessemer Venture Partners. This investment aims to accelerate the development of Graph AI’s flagship platform, Graph Safety, which leverages artificial intelligence to automate and enhance the monitoring of adverse drug events (ADEs) throughout a drug's lifecycle.
Addressing Challenges in Pharmacovigilance
Pharmacovigilance—the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems—is a critical component
...
